Search

Publications

Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors
Atallah E, Mauro MJ, Hochhaus A, Boquimpani C, Minami Y, Maheshwari VK, Saini L, Corbin R, Réa D.

EHA Ranking 2025

The information on this page is also available as a printable PDF. EHA Ranking 2025 — PDF version

Position
Company
Priority points
Corporate Level

1
Johnson & Johnson 
1. 488,82 
Platinum 

2
Bristol Myers Squibb 
1.

SWG Educational Activities

Social and public activitiesSince 2020, Prof Hermann Einsele has been a Councilor to the EHA Board. Scientific activitiesFifth European CAR T-cell meetingDateFebruary 9–11, 2023. LocationRotterdam, The Netherlands.